The problem with Her2-low testing
Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.
When is big pharma no longer big pharma?
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
GSK’s “crown jewels” already look tarnished
As the company pulls Blenrep, questions about its future will only intensify.
Merck opens its mind to epigenetics with Imago buy
The purchase sets up another showdown with the group’s old rival, Bristol Myers Squibb, in LSD1 inhibition.
Big medtechs’ efficiency starts to recover from Covid
Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.
Lantheus has three shots on goal to challenge Novartis
Two days after tying up with Point the company outlines plans to dominate PSMA-based prostate cancer screening and treatment.
